GlioblastomaNCT00392548
URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol
An observational study of Glioblastoma, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.
Trial summary
Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with glioblastoma, receiving standard therapy. Hypothesis: that urinary VEGF levels can serve as a predictor of treatment response and survival. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glioblastoma
- How many people
- 130 participants
- Where
- 1 siteIsrael
- Study dates
- Oct 2006to Oct 2006
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
- Patient must meet the eligibility requirements for the RTOG treatment study. (If the patient is deemed retrospectively ineligible for the RTOG treatment study, the patient will likewise be ineligible for this study.)
- Patient must sign a study-specific informed consent for RTOG 0611 prior to study entry.
Who cannot join
- Patient not able to receive 6000 cGy of radiation therapy.
Trial locations and contacts
1 site in 1 country.
Israel1 site
tel Aviv Sourasky Medical Center
Tel Aviv, 64239
Deborah T Blumenthal, MD
Felix Bokstein, MD
About this study
Official title: Urinary VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with glioblastoma, receiving standard therapy.
Hypothesis: that urinary VEGF levels can serve as a predictor of treatment response and survival.
Read the detailed description
Measurement of urinary VEGF levels pre treatment,immediately after treatment, and 1 month after treatment
- Conditions
- Glioblastoma
- Keywords
- GBM, glioblastoma, urine, VEGF, radiation, Patients must be enrolled to an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
- Medical subject headings
- Glioblastoma
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2006 (estimated)
- Study startOct 2006
- Study completionOct 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlioblastomaStudies of the same condition, open and under way.
- More trials run by Tel-Aviv Sourasky Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Defined population
- Time perspective
- Prospective
- Enrolment
- 130 participants
Sponsor and investigators
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Sponsor type
- Other government
- Collaborators
- Radiation Therapy Oncology Group
- Investigators
- Deborah T Blumenthal, MD, Principal investigator, Tel-Aviv Sourasky Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00392548
- Sponsor's protocol ID
- RTOG0611
- Status last verified
- Sep 2006
- First submitted
- 25 Oct 2006
- Last updated
- 26 Oct 2006
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2006. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Urinary VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
- ClinicalTrials.gov ID
- NCT00392548
- Acronym / sponsor ID
- RTOG0611
- Conditions
- Glioblastoma
- Keywords
- GBM, glioblastoma, urine, VEGF, radiation, Patients must be enrolled to an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 130 participants
- Lead sponsor
- Tel-Aviv Sourasky Medical CenterOther government
- Collaborators
- Radiation Therapy Oncology Group
- Study start
- Oct 2006
- Study completion
- Oct 2006
- First posted
- 26 Oct 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with glioblastoma, receiving standard therapy.
Hypothesis: that urinary VEGF levels can serve as a predictor of treatment response and survival.
Detailed description
Measurement of urinary VEGF levels pre treatment,immediately after treatment, and 1 month after treatment
Study design
- Observational model
- Defined population
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
- Patient must meet the eligibility requirements for the RTOG treatment study. (If the patient is deemed retrospectively ineligible for the RTOG treatment study, the patient will likewise be ineligible for this study.)
- Patient must sign a study-specific informed consent for RTOG 0611 prior to study entry.
Key exclusion criteria (1 listed)
- Patient not able to receive 6000 cGy of radiation therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2006.
Related trials for Glioblastoma
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Active, not recruitingPhase 1
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Glioblastoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Deborah T Blumenthal, MD principal investigator
Tel-Aviv Sourasky Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glioblastoma, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Oct 2006. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Deborah T Blumenthal, MD (011972524266304, deborahblumenthal@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2006.